Drug Search Results
More Filters [+]

SYP-1018

Alternative Names: syp-1018, syp1018, syp 1018
Latest Update: 2012-12-24
Latest Update Note: Clinical Trial Update

Product Description

Samyang was developing syp-1018, an intravenous CYP51 Inhibitor for Systemic Mycotic Infection

Mechanisms of Action: CYP51 Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Samyang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SYP-1018

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Vfend

P1

Completed

Healthy Volunteers

2012-11-01

Recent News Events

Date

Type

Title